Kurt Von Emster Sells 18,831 Shares of CymaBay Therapeutics Inc (CBAY) Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 18,831 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $12.14, for a total transaction of $228,608.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, February 2nd, Kurt Von Emster sold 90,098 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.15, for a total transaction of $1,094,690.70.
  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.26, for a total transaction of $463,444.48.

CymaBay Therapeutics Inc (CBAY) traded up $0.71 during mid-day trading on Wednesday, reaching $12.50. 1,159,179 shares of the company’s stock were exchanged, compared to its average volume of 819,691. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics Inc has a 12 month low of $1.92 and a 12 month high of $12.77. The firm has a market capitalization of $548.30, a PE ratio of -12.38 and a beta of 2.04.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same period in the prior year, the business earned ($0.25) EPS. equities analysts predict that CymaBay Therapeutics Inc will post -0.87 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 140 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in CymaBay Therapeutics during the fourth quarter worth approximately $115,000. Sigma Planning Corp raised its holdings in CymaBay Therapeutics by 82.0% during the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 12,300 shares in the last quarter. Ardsley Advisory Partners raised its holdings in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in CymaBay Therapeutics during the third quarter worth approximately $404,000. 54.70% of the stock is currently owned by institutional investors.

CBAY has been the topic of several analyst reports. Roth Capital reaffirmed a “buy” rating and issued a $27.00 target price on shares of CymaBay Therapeutics in a report on Thursday, January 25th. BidaskClub raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 26th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. CymaBay Therapeutics has an average rating of “Buy” and an average price target of $16.56.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/07/kurt-von-emster-sells-18831-shares-of-cymabay-therapeutics-inc-cbay-stock.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply